BioSpace News Archive

Agomab Therapeutics NV announced that it has dosed the first subject in a first-in-human Phase 1 clinical study of AGMB-447, an inhaled lung-restricted small molecule inhibitor of ALK5.

Alkermes plc announced that it has entered into a definitive agreement to sell its development and manufacturing facility in Athlone, Ireland to Novo Nordisk, a leading global healthcare company.

Clearside Biomedical, Inc. (Nasdaq: CLSD) announced today that it has completed randomization in its ODYSSEY Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) in neovascular age-related macular degeneration (wet AMD).

Apellis Pharmaceuticals, Inc. announced an update on the ongoing review of its marketing authorization application for intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration by the Committee for Medicinal Products for Human Use of the European Medicines Agency.

Carisma Therapeutics Inc. (Nasdaq: CARM) (“Carisma” or the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination of its first lead candidate under the collaboration with Moderna, Inc. (Nasdaq: MRNA).

Neochromosome, Inc., a biotechnology company focused on genome-scale cell engineering and a wholly owned subsidiary of Opentrons Labworks, Inc., announced a collaboration with Dr. Giovanni Stracquadanio of the University of Edinburgh utilizing artificial intelligence and machine learning to accelerate the development of new and more stable enzymes.

Bicycle Therapeutics is hosting a Research & Development Day for investors and analysts in New York to provide clinical updates for BT8009, BT7480 and BT5528, and an overview of the company’s strategy and pipeline opportunities.

Nucleus RadioPharma, the world’s first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, announced the appointment of Kathy Spencer-Pike as Chief Commercial Officer.

IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the three months ended October 31, 2023.

AbelZeta Pharma, Inc. announced an amendment of its worldwide collaboration and license agreement with Janssen Biotech, Inc., a Johnson & Johnson company.